MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $2.39M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding INKT, Q2 2026
No superinvestor reported holding INKT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by MiNK Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Ryan BarbaraDirector | SSale | −1.50K | $12.76 | −$19.1K | −6.4%22.0K after | 2 lots |
| Mar 11, 2026 (view filing) | Mar 9-10 | 2 days | Ryan BarbaraDirector | SSale | −1.50K | $14.70 | −$22.1K | −6.8%20.4K after | 4 lots |
| Mar 4, 2026 (view filing) | Feb 27-Mar 2 | 5 daysLate | Ryan BarbaraDirector | SSale | −500 | $10.85 | −$5.43K | −2.2%21.9K after | 2 lots |
| Oct 16, 2023 (view filing) | Oct 12-16 | 4 days | Agenus Inc10% Owner | PPurchase | +23.0K | $1.10 | +$25.3K | +0.1%21.8M after | 3 lots |
| Oct 6, 2023 (view filing) | Oct 4 | 2 days | Agenus Inc10% Owner | PPurchase | +15.0K | $1.09 | +$16.4K | +0.1%21.7M after | |
| Aug 31, 2023 (view filing) | Aug 29 | 2 days | Agenus Inc10% Owner | PPurchase | +29.7K | $1.52 | +$45.1K | +0.1%21.7M after | |
| Aug 28, 2023 (view filing) | Aug 24-28 | 4 days | Agenus Inc10% Owner | PPurchase | +183.1K | $1.53 | +$280.7K | +0.9%21.7M after | 2 lots |
| May 12, 2023 (view filing) | May 10-11 | 2 days | Agenus Inc10% Owner | PPurchase | +45.4K | $1.47 | +$66.7K | +0.2%21.6M after | 2 lots |
| May 4, 2023 (view filing) | May 2 | 2 days | Armen Garo HDirector | PPurchase | +100.0K | $0.95 | +$95.0K | +5.3%1.98M after | |
| Jul 21, 2022 (view filing) | Jul 18-19 | 3 daysLate | Wiinberg UlfDirector | PPurchase | +20.0K | $1.38 | +$27.6K | +7.2%298.3K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in MiNK Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 68,660 | $802.6K | 0.00% | +9,296+15.7% | Added |
| DnB Asset Management AS | 55,142 | $644.6K | 0.00% | +55,142 | New |
| Longbow Finance SA | 16,667 | $194.8K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,573 | $182.1K | 0.00% | −1,772−10.2% | Reduced |
| Citadel Advisors LLC | 15,440 | $180.5K | 0.00% | +15,440 | New |
| BlackRock, Inc. | 13,382 | $156.4K | 0.00% | +7,179+115.7% | Added |
| Vanguard Fiduciary Trust Co | 8,287 | $96.9K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,885 | $57.1K | 0.00% | −10,317−67.9% | Reduced |
| Steward Partners Investment Advisory, LLC | 2,000 | $23.4K | 0.00% | 00.0% | Unchanged |
| US Bancorp | 1,995 | $23.3K | 0.00% | +1,995 | New |